 Due
to the inherent risks of central venous access, CVP is
only monitored for critically ill patients who need comprehensive
hemodynamic monitoring. Approximately 3 million central
lines are placed in the United States annually, which
cost $5,000 per procedure and represent a total cost of
$15 billion. Although central
venous access procedures are
the gold standard, they carry frequent risks of infection
and result in 150,000 cases of catheter-related bloodstream
infections (CRBSIs) a year, leading to annual treatment
costs of $2 billion to healthcare providers and insurers.
cVein™ will provide significant value for physicians
and healthcare providers in several ways:
Reduction of Catheters –
cVein™ reduces the need for costly central venous
access procedures and eliminates the risks of infection
and bleeding associated with catheters. If cVein™
eliminated the need for even 10% of all invasive catheterization
procedures, procedural costs could be cut by $1.5 billion
per year.
Earlier Removal of Catheters –
Physicians often have to balance the need for hemodynamic
monitoring with the risk of leaving the patient attached
to a central line. With cVein™, doctors have the
option to continue monitoring CVP after the catheter is
removed. If earlier removal reduced the rate of CRBSIs
by 10%, it would lead to a cost reduction of $200 million
for the healthcare system. |
